🇺🇸 FDA
Patent

US 12263202

Method of treating melanocortin-4 receptor pathway-associated disorders

granted A61KA61K38/00A61K38/12

Quick answer

US patent 12263202 (Method of treating melanocortin-4 receptor pathway-associated disorders) held by RHYTHM PHARMACEUTICALS, INC. expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
RHYTHM PHARMACEUTICALS, INC.
Grant date
Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K38/00, A61K38/12, A61K9/0019, A61P